Hoodia for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Hoodia for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Desert plant chewed to blunt hunger. Evidence for appetite suppression and weight loss is conflicted, and every study was paid for by a company selling or developing the product. Harms are clearer: raised blood pressure and pulse, nausea, vomiting, odd skin sensations, shifted liver markers, muscle loss in animals. Many products contain another plant, no Hoodia, or an undeclared drug. (Full Review)

Protocol

Trial-derived regimen
2 × 1110 mg/day
Purified Hoodia gordonii extract, one hour before breakfast and dinner, for 15 days. Produced adverse effects without measurable appetite or weight benefit.
European regulatory ceiling
9.4 mg/day
Dried Hoodia parviflora aerial parts judged safe only up to this amount, two orders of magnitude below retail extract labelling.
Best time of day
1 h before the two largest meals
Late-evening dosing is best avoided given the stimulant profile and its potential effect on sleep onset.
Time to effect
Body measurements
40 days
Body-measurement change in the whole-plant Hoodia parviflora trial.
Subjective appetite
Within 10 days
Subjective appetite change, where reported, appeared within the first ten days.
Purified extract
Nothing at 15 days
The controlled extract trial saw nothing at 15 days.

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Uncontrolled hypertension (≥ 140/90 mmHg on treatment)
  • Corrected QT interval above 440 milliseconds, atrial or ventricular arrhythmia, family history of premature sudden cardiac death
  • Resting heart rate below 50 or above 100 beats per minute, or left ventricular hypertrophy
  • Active or recent liver disease, or liver enzymes above twice the upper limit of normal
  • History of an eating disorder, or body mass index below 20 kg/m²
  • Adults over 70, diagnosed sarcopenia, or unintentional weight loss
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline)
  • Stimulants and sympathomimetics (pseudoephedrine, high-dose caffeine, ephedra, yohimbine, phenylephrine)
  • Narrow-margin CYP3A4 or P-glycoprotein substrates that cannot be monitored
Key Interactions
  • CYP3A4 substrates (simvastatin, midazolam, tacrolimus, apixaban)
  • P-glycoprotein substrates (digoxin, dabigatran, rivaroxaban, colchicine)
  • Antihypertensives and rate-control agents (amlodipine, lisinopril, bisoprolol)
  • Over-the-counter agents (decongestant cold remedies, caffeine tablets, weight-loss patches, laxative teas)
  • Supplements with additive stimulant or heat-producing effects (bitter orange, green tea extract, guarana, Acacia rigidula, forskolin)
  • Supplements with additive hepatic burden (green tea extract, kava, Garcinia cambogia, high-dose niacin)
  • GLP-1 receptor agonists (semaglutide), aggressive caloric restriction, prolonged fasting

Risk & Side Effects

  • High: Adulterated, substituted or undeclared-drug products
    •
  • Medium: Blood pressure and heart rate elevation; nausea and vomiting; altered skin sensation; liver-related laboratory abnormalities
  • Low: Liver injury from multi-ingredient or adulterated products; loss of lean muscle mass
  • Speculative: Cardiac hypertrophy; impaired fetal development; blunted thirst signalling

Monitoring

Marker Target Why
Blood pressure 105–120 / 65–78 mmHg; no rise above 10 mmHg systolic from personal baseline The endpoint that rose significantly on Hoodia extract
Resting heart rate 50–70 beats per minute; no rise above 8 beats from personal baseline Second component of the sympathomimetic signal
Corrected QT interval Below 430 milliseconds Screens for the conduction risk that makes stimulant load dangerous
Alanine aminotransferase 10–26 U/L (women), 10–30 U/L (men) Detects liver-cell injury, the registry-level concern
Alkaline phosphatase 45–90 U/L Rose significantly on extract in the controlled trial
Total bilirubin 0.3–0.9 mg/dL Second liver marker that rose in the same trial
Blood urea nitrogen 12–18 mg/dL Fell significantly on extract; also tracks protein intake
Fasting glucose 75–90 mg/dL Tests the proposed insulin-secretion pathway
Glycated haemoglobin 4.8–5.3% Confirms whether any glucose change persists
Fat-free mass No established target; track change from personal baseline, aiming for no loss The lean-mass loss seen in rodents is the main longevity-relevant harm

Cadence: Home blood pressure and resting heart rate every second day; liver panel and blood urea nitrogen repeated at day 15; electrocardiogram repeated at day 15 if any cardiovascular symptom appears; full panel monthly beyond 30 days; body composition and full panel four weeks after stopping.

Qualitative Assessment

  • Hunger and craving intensity, scored once daily at a fixed time on a 0–10 scale
  • Nausea, vomiting or early fullness, recorded as present or absent after each dose
  • Skin sensations — tingling, numbness or crawling
  • Palpitations, restlessness or a sense of heightened arousal, especially in the evening
  • Sleep onset latency and subjective sleep quality
  • Training quality: session energy, load maintained, and recovery between sessions
  • Any jaundice, dark urine, pale stool or right upper abdominal discomfort — immediate stop signals
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.